GlassScriptPhysician profile
Jonathan P Faro
NPI 1508155987
$5,625.62
in general payments reported to CMS, 2019-2025
34 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $2,415 · 2021: $299 · 2022: $220 · 2023: $783 · 2024: $690 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,746.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acessa Health INC. | $2,885.20 | 2019-2020 | |
| Abbvie INC. | $326.01 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $270.19 | 2023-2025 | |
| Pfizer INC. | $224.62 | 2022-2025 | |
| W. L. Gore & Associates, INC. | $207.41 | 2024 | Gore Cardioform Septal Occluder |
| Sumitomo Pharma America, INC. | $183.94 | 2023 | Myfembree |
| Shield Therapeutics INC | $165.23 | 2023-2024 | Accrufer |
| Gynesonics, INC. | $152.35 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Astellas Pharma US INC | $136.96 | 2022-2024 | Veozah, Myrbetriq |
| Boston Scientific Corporation | $131.03 | 2020-2023 | |
| Myriad Women'S Health, INC. | $127.99 | 2023 | Myrisk |
| Evofem Biosciences, INC. | $107.12 | 2021-2025 | Phexxi, Solosec, Phexx |
| Hologic Sales and Service, LLC | $83.27 | 2019-2024 | Acessa Provu System |
| Allergan, INC. | $67.11 | 2019-2020 | |
| Avion Pharmaceuticals | $65.71 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $51.10 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $47.10 | 2025 | Exparel |
| Smith+Nephew, INC. | $42.63 | 2019-2023 | Oasis Micro |
| Horizon Therapeutics Plc | $39.56 | 2019 | |
| Dysis Medical, INC. | $35.13 | 2021 | |
| Exeltis, USA INC. | $34.78 | 2024-2025 | Slynd |
| Innovation Technologies INC | $28.81 | 2024 | Irrisept |
| Dexcom, INC. | $25.50 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $24.94 | 2021 | |
| Organon LLC | $23.79 | 2023 | Nexplanon |
| Covidien LP | $23.61 | 2019 | |
| Merck Sharp & Dohme LLC | $17.39 | 2021 | |
| Abbott Laboratories | $17.22 | 2022 | |
| Lupin INC. | $16.71 | 2019 | |
| Coopersurgical, INC. | $13.64 | 2019 | |
| Ethicon US, LLC | $12.99 | 2021 | |
| Ascend Therapeutics US, LLC | $12.86 | 2020 | |
| Medtronic, INC. | $12.68 | 2022 | |
| Minerva Surgical, INC | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Faro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.